Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Lacosamide Oral Solution, 10 mg/mL. Glenmark`s Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat�2 Oral Solution, 10 mg/mL of UCB, Inc. According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat� Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million. Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Glenmark`s Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z�2 Ophthalmic Solution USP, 0.004% of Sandoz, Inc. According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Z� Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million. Powered by Capital Market - Live News

Net profit of Glenmark Pharmaceuticals reported to Rs 354.21 crore in the quarter ended September 2024 as against net loss of Rs 81.95 crore during the previous quarter ended September 2023. Sales rose 7.59% to Rs 3400.50 crore in the quarter ended September 2024 as against Rs 3160.69 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3400.503160.69 8 OPM %17.7014.63 - PBDT592.85342.53 73 PBT472.57201.07 135 NP354.21-81.95 LP Powered by Capital Market - Live News

Net profit of Glenmark Pharmaceuticals rose 96.81% to Rs 595.06 crore in the quarter ended September 2024 as against Rs 302.35 crore during the previous quarter ended September 2023. Sales rose 19.56% to Rs 2594.89 crore in the quarter ended September 2024 as against Rs 2170.40 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2594.892170.40 20 OPM %30.0120.43 - PBDT849.91458.89 85 PBT795.06409.04 94 NP595.06302.35 97 Powered by Capital Market - Live News

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live News